Cybin Inc Stock Today
| CYBN Stock | USD 10.64 0.82 8.35% |
Performance1 of 100
| Odds Of DistressOver 53
|
Cybin is selling at 10.64 as of the 26th of November 2024; that is 8.35 percent increase since the beginning of the trading day. The stock's open price was 9.82. Cybin has 53 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Cybin Inc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 13th of September 2019 | Category Healthcare | Classification Health Care |
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. It has also developed EMBARK, a psychedelic-assisted psychotherapy. Cybin operates under Biotechnology classification in the United States and is traded on AMEX Exchange. The company has 19.99 M outstanding shares of which 609.73 K shares are currently shorted by private and institutional investors with about 4.07 trading days to cover. More on Cybin Inc
Moving against Cybin Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cybin Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CoFounder | Eric LLB | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCybin can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cybin's financial leverage. It provides some insight into what part of Cybin's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cybin Inc (CYBN) is traded on NYSE MKT Exchange in USA. It is located in 100 King Street West, Toronto, ON, Canada, M5X 1C9 and employs 50 people. Cybin is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 202.44 M. Cybin Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 19.99 M outstanding shares of which 609.73 K shares are currently shorted by private and institutional investors with about 4.07 trading days to cover.
Cybin Inc currently holds about 30.21 M in cash with (68.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.17.
Check Cybin Probability Of Bankruptcy
Ownership AllocationCybin holds a total of 19.99 Million outstanding shares. 30% of Cybin Inc outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cybin Ownership Details
Cybin Historical Income Statement
Cybin Stock Against Markets
Cybin Corporate Management
| Erica Olson | VP Controller | Profile | |
| Alex Nivorozhkin | Chief Officer | Profile | |
| Greg Cavers | Chief Officer | Profile | |
| Gabriel Fahel | Chief Secretary | Profile | |
| John Kanakis | CoFounder | Profile | |
| Douglas Drysdale | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cybin Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cybin. If investors know Cybin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cybin listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.12) | Return On Assets (0.33) | Return On Equity (0.49) |
The market value of Cybin Inc is measured differently than its book value, which is the value of Cybin that is recorded on the company's balance sheet. Investors also form their own opinion of Cybin's value that differs from its market value or its book value, called intrinsic value, which is Cybin's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cybin's market value can be influenced by many factors that don't directly affect Cybin's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cybin's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cybin is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cybin's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.